Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 54 clinical trials
Featured trial
AREN0534: Treatment for Patients with Bilateral, Multicentrick or Bilaterally-Predisposed Unilateral Wilms Tumor

AREN0534: Treatment for Patients with Bilateral, Multicentrick or Bilaterally-Predisposed Unilateral Wilms Tumor

  • 08 Nov, 2020
  • 1 location
Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients

In this phase I/II trial, the primary objective is to determine overall and progression-free survival of patients with newly diagnosed glioblastoma when autologous Wilms' tumor 1 (WT1) messenger

  • 28 Jan, 2021
  • 1 location
Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.

peptide vaccine designed to induce cytotoxic T lymphocytes that recognize Wilms Tumor Gene 1 (WT1) peptides.

  • 14 Mar, 2021
  • 1 location
Galacto-oligosaccharides and Intestinal Activity

Dietary intake of galacto-oligosaccharides (GOS) may have beneficial effects on host health by affecting the microbiota composition and -activity. So far studies focused on analyses in fecal samples, while the primary site of carbohydrate fermentation is the proximal colon. To date, no studies have been performed in humans on the …

Accepts healthy volunteers
  • 10 Apr, 2023
  • 1 location
Individualized Antibiotic Therapy in Children With Acute Uncomplicated Febrile Urinary Tract Infection

An investigator-initiated, open-label, multi-center, randomized, non-inferiority trial of children aged 3 months to 13 years with acute uncomplicated febrile urinary tract infection. The primary objective is to determine whether individualized antibiotic therapy based on an algorithm (experimental arm) versus standard antibiotic therapy of 10 days (control arm) can reduce the …

  • 06 Apr, 2023
  • 4 locations
Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients

Trial participants are randomised within 14 days after liver transplantation surgery in a 1:1 ratio to two alternative treatment arms containing either Envarsus® (test arm) or Advagraf® (comparator arm) as first-line calcineurin inhibitor within a standard-of-care immunosuppressive regimen. Tacrolimus blood trough levels and drug doses are monitored at regular intervals …

  • 30 May, 2022
  • 15 locations
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms

  • 20 Sep, 2023
  • 103 locations
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first …

high-risk neuroblastoma
colony stimulating factor
monoclonal antibodies
bone marrow procedure
  • 07 Oct, 2022
  • 23 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

autologous stem cell infusion
cns tumors
  • 16 Sep, 2023
  • 107 locations
Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, PK, and biomarker study of PBI-200 in subjects with NTRK-fusion-positive advanced or metastatic solid tumors.

measurable disease
systemic therapy
  • 07 Apr, 2023
  • 26 locations